Upregulation of PEDF Expression by PARP Inhibition Contributes to the Decrease in Hyperglycemia-Induced Apoptosis in HUVECs.

Haibing Chen,Weiping Jia,Xun Xu,Ying Fan,Dongqing Zhu,Haixiang Wu,Zhenggao Xie,Zhi Zheng
DOI: https://doi.org/10.1016/j.bbrc.2008.02.100
IF: 3.1
2008-01-01
Biochemical and Biophysical Research Communications
Abstract:Poly(ADP-ribose)polymerase (PARP) inhibitors decrease angiogenesis through reducing vascular endothelium growth factor (VEGF) induced proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs). In contrast to VEGF, pigment epithelium-derived factor (PEDF) has been demonstrated to act as a strong endogenous inhibitor of angiogenesis. Here, we show that PARP inhibition with a specific inhibitor PJ-34 or specific PARP antisense oligonucleotide upregulates hyperglycemia-induced PEDF expression in HUVECs in a dose-dependent manner. This results in the retard of activation of p38 MAP kinase and the concomitant decrease in cell apoptosis. These results give the first direct demonstration that PEDF might represent a target for PARP inhibition treatment and the effects of PEDF on endothelial cells growth are context dependent.
What problem does this paper attempt to address?